Bibliografia ❖ Abbate A, Biondi-Zoccai GG, Agostoni P, Lipinski MJ, Vetrovec GW. Recurrent angina after coronary revascularization: a clinical challenge. Eur Heart J. 2007 May;28(9):1057-65. doi: 10.1093/eurheartj/ehl562. Epub 2007 Mar 23. PMID: 17384090. ❖ Agarwal S, Schechter C, Zaman A. Assessment of functional status and quality of life after percutaneous coronary revascularisation in octogenarians. Age and Ageing. 2009;38(6):748-51. ❖ Al-Lamee RK, Nowbar AN, Francis DP. Percutaneous coronary intervention for stable coronary artery disease. Heart. 2019 Jan;105(1):11-19. doi: 10.1136/heartjnl-2017-312755. Epub 2018 Sep 21. PMID: 30242142. ❖ Allan Davies, Kim Fox, Alfredo R Galassi, Shmuel Banai, Seppo Ylä-Herttuala, Thomas F Lüscher, Management of refractory angina: an update, European Heart Journal, Volume 42, Issue 3, 14 January 2021, Pages 269– 283, https://doi.org/10.1093/eurheartj/ehaa820 ❖ Anna Palmisano et al. “Feature tracking and mapping analysis of myocardial response to improved perfusion reserve in patients with refractory angina treated by coronary sinus Reducer implantation: a CMR study” The Int. J. of Cardiovascular Imaging Accepted: 6 August 2020 ❖ Aranda JM Jr, Hill J. Cardiac transplant vasculopathy.
Chest. 2000 Dec;118(6):1792-800. doi:
10.1378/chest.118.6.1792. PMID: 11115475. ❖ Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, et al. Effects of Enhanced External Counterpulsation on Health-Related Quality of Life Continue 12 Months After Treatment: A Substudy of the Multicenter Study of Enhanced External Counterpulsation, 2002). ❖ Arora RR, Chou TM, Jain D, Fleishman B, Crawford L, McKiernan T, et al. Effects of Enhanced External Counterpulsation on Health-Related Quality of Life Continue 12 Months After Treatment: A Substudy of the Multicenter Study of Enhanced External Counterpulsation. Journal of Investigative Medicine. 2002;50(1):25. ❖ Banai S, Ben Muvhar S, Parikh KH, Medina A, Sievert H, Seth A, et al. Coronary sinus reducer stent for the treatment of chronic refractory angina pectoris: a prospective, open-label, multicenter, safety feasibility firstin-man study. J Am Coll Cardiol. 2007;49(17):1783-9. ❖ Bazoukis G, Brilakis ES, Tse G, Letsas KP, Kitsoulis P, Liu T, et al. The efficacy of coronary sinus reducer in patients with refractory angina-A systematic review of the literature. J. 2018;31(6):775-9. ❖ Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, Ponder KP, Roberts WC, Rosenfeld HM, Giugliani R. Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis. 2011 Dec;34(6):1183-97. doi: 10.1007/s10545-011-9359-8. Epub 2011 Jul 9. PMID: 21744090; PMCID: PMC3228957. ❖ Bugiardini R, Bairey Merz CN. Angina with "normal" coronary arteries: a changing philosophy. JAMA. 2005 Jan 26;293(4):477-84. doi: 10.1001/jama.293.4.477. PMID: 15671433. ❖ Cannon RO 3rd, Epstein SE. "Microvascular angina" as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol. 1988 Jun 1;61(15):1338-43. doi: 10.1016/0002-9149(88)91180-0. PMID: 3287885. ❖ Carlo Zivelonghi et al. “Coronary sinus Reducer implantation results in improved oxygen kinetics at cardiopulmonary exercise test in patients with refractory angina.” Accepted: 17 February 2020 EuroIntervention 2020; Jaa-735 2020, doi: 10.4244/EIJ-D-19-00766
